Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.23.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:    
Research and development $ 43,813 $ 32,486
General and administrative 12,177 9,357
Total operating expenses 55,990 41,843
Operating loss (55,990) (41,843)
Non-operating income (expense):    
Interest and other income, net 4,208 80
Gain (loss) from change in fair value of derivative liabilities (5) 6,545
Employee retention credit   231
Underwriting discount on issuance of derivative   (2,495)
Interest expense   (1,807)
Loss on extinguishment of loan agreement   (1,771)
Total non-operating income (expense), net 4,203 783
Net loss (51,787) (41,060)
Other comprehensive loss:    
Net unrealized loss on available-for-sale marketable debt securities (351)  
Comprehensive loss $ (52,138) $ (41,060)
Net loss per common share - basic (in dollars per share) $ (1.01) $ (2.26)
Net loss per common share - diluted (in dollars per share) $ (1.01) $ (2.32)
Weighted average number of common shares outstanding - basic (in shares) 51,187 18,197
Weighted average number of common shares outstanding - diluted (in shares) 51,187 19,487